Disease

Neoplasms, Glandular and Epithelial

Late-stage therapeutic developmentEmerging researchRising momentum

MeSHNeoplasms, Glandular and Epithelial

Publications

Clinical trials

Related conditions

Related treatments

Related proteins

2023

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Genomic characterization of thymic epithelial tumors in a real-world dataset.

Research2023-09-12ESMO open

The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.

Research2023-09-09Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Research2019-11-01The New England journal of medicine

A phase 3 trial of bevacizumab in ovarian cancer.

Research2011-12-01The New England journal of medicine

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate

Key developments

6 clinical trials expected to report results, the earliest in Q1 2029.

Upcoming Milestones

Major developments

Upcoming trial readoutHigh impact

Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

Results expected Q1 20292026-07-10

Upcoming trial readoutHigh impact

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

Results expected Q4 20302026-07-02

Clinical Milestones11View all 11

Results expected 5

2026-07-10Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell CarcinomaResults expected Q1 2029
2026-07-02A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal AdenocarcinomaResults expected Q4 2030
2026-07-02Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon CancerResults expected Q2 2034
2026-05-08A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)Results expected Q2 2029
2026-04-06A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-Line Treatment of Unresectable Recurrent and/or Metastatic HPV16+ Head and Neck Squamous Cell CarcinomaResults expected Q1 2029

Other updates 5

+3 more in the activity timeline below

Activity timeline11

2032-04-01ClinicalA Randomized Double-blinded Phase 2/3 Study of HB-202/HB-201 Alternating 2-Vector Therapy With Pembrolizumab Versus Pembrolizumab-Only for First Line HPV16+ High PD-L1 CPS Recurrent and/or Metastatic Oropharyngeal Squamous Cell CarcinomaWithdrawn
2031-07-01ClinicalRandomized Double-Blind Placebo Controlled Phase II Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell CarcinomaWithdrawn
2030-05-06ClinicalA Phase 2 Peri-Operative Study of Treatment With Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Patients With Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)Withdrawn
2028-05-31ClinicalPhase II Trial of Xevinapant and Chemoradiotherapy in Adjuvant Treatment for Patients With Head and Neck Squamous Cell Carcinoma With High Risk Pathologic FeaturesWithdrawn
2027-12-31ClinicalCAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)Withdrawn
2026-07-10ClinicalPhase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell CarcinomaResults expected Q1 2029
2026-07-02ClinicalA Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal AdenocarcinomaResults expected Q4 2030
2026-07-02ClinicalRandomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon CancerResults expected Q2 2034
2026-05-08ClinicalA Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)Results expected Q2 2029
2026-04-06ClinicalA Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-Line Treatment of Unresectable Recurrent and/or Metastatic HPV16+ Head and Neck Squamous Cell CarcinomaResults expected Q1 2029

Research-associated treatments

Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.

Carboplatin2 Paclitaxel2

Clinical trials

12 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer

Phase 2/3 · Active, not recruiting · Alliance for Clinical Trials in Oncology

Phase 3 · Active, not recruiting · Arcus Biosciences, Inc.

Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

Phase 3 · Active, not recruiting · ECOG-ACRIN Cancer Research Group

Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

Phase 2/3 · Active, not recruiting · Alliance for Clinical Trials in Oncology

A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)

Phase 2/3 · Active, not recruiting · Inhibrx Biosciences, Inc

A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-Line Treatment of Unresectable Recurrent and/or Metastatic HPV16+ Head and Neck Squamous Cell Carcinoma

Phase 3 · Active, not recruiting · PDS Biotechnology Corp.

Recently completed

S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study

Phase 2 · Completed · Fudan University

Phase III Trial Comparing a 28 Day Schedule of Daily Oral 5-FU Plus Eniluracil to Protracted Intravenous Infusion in Previously Untreated Patients With Advanced Colorectal Cancer

Phase 3 · Completed · National Cancer Institute (NCI)

Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer

Phase 3 · Completed · National Cancer Institute (NCI)

Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer

Phase 3 · Completed · National Cancer Institute (NCI)

A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU

Phase 3 · Completed · National Cancer Institute (NCI)

First Prospective Intergroup Translational Research Trial Assessing the Potential Predictive Value of p53 Using a Functional Assay in Yeast in Patients With Locally Advanced/Inflammatory or Large Operable Breast Cancer Prospectively Randomised to a Taxane Versus a Non Taxane Regimen

Phase 3 · Completed · European Organisation for Research and Treatment of Cancer - EORTC

Research activity

4 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time

20112023

Most influential

A phase 3 trial of bevacizumab in ovarian cancer.

The New England journal of medicine · 2011 · 1,607 cites

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

The New England journal of medicine · 2019 · 220 cites

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023 · 47 cites

Genomic characterization of thymic epithelial tumors in a real-world dataset.

ESMO open · 2023 · 21 cites

Recent publications

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023 · 47 cites

Genomic characterization of thymic epithelial tumors in a real-world dataset.

ESMO open · 2023 · 21 cites

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

The New England journal of medicine · 2019 · 220 cites

A phase 3 trial of bevacizumab in ovarian cancer.

The New England journal of medicine · 2011 · 1,607 cites

Major themes6

Neoplasms, Glandular and Epithelial2
Thymoma2
Thymus Neoplasms2
Cytoreduction Surgical Procedures1
Lung Neoplasms1
Neuroendocrine Tumors1

Leading journals3

The New England journal of medicine2
ESMO open1
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer1

Leading researchers8

Ahmad U1
Alvarez Secord A1
Appel S1
Armstrong DK1
Asamura H1
Basen-Engquist K1
Beale P1
Bille A1

Affiliations (unnormalised)6

and Thoracic Institute at Cleveland Clinic1
Ankara University Faculty of Medicine1
Asan Medical Center1
Azienda Ospedaliero-Universitaria Pisana1
Baggiovara Civil Hospital1
Chaim Sheba Medical Center1

Disease biology

1 match

Key proteins & gene products studied in this disease. Number shows shared papers.

Bevacizumab2

Related conditions

3 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Ovarian Neoplasms2 Thymoma2 Thymus Neoplasms2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.

Identifiers

MeSHNeoplasms, Glandular and Epithelial

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.